Další formáty:
BibTeX
LaTeX
RIS
@article{1751716, author = {Schjesvold, F. and Robak, P. and Pour, Luděk and Aschan, J. and Sonneveld, P.}, article_location = {London}, article_number = {11}, doi = {http://dx.doi.org/10.2217/fon-2020-0024}, keywords = {alkylating agent; melflufen; MM; multiple myeloma; Phase III study; relapsed refractory multiple myeloma; RRMM}, language = {eng}, issn = {1479-6694}, journal = {Future Oncology}, title = {OCEAN: a randomized Phase III study of melflufen plus dexamethasone to treat relapsed refractory multiple myeloma}, url = {https://www.futuremedicine.com/doi/10.2217/fon-2020-0024?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed}, volume = {16}, year = {2020} }
TY - JOUR ID - 1751716 AU - Schjesvold, F. - Robak, P. - Pour, Luděk - Aschan, J. - Sonneveld, P. PY - 2020 TI - OCEAN: a randomized Phase III study of melflufen plus dexamethasone to treat relapsed refractory multiple myeloma JF - Future Oncology VL - 16 IS - 11 SP - 631-641 EP - 631-641 PB - Future Medicine Ltd. SN - 14796694 KW - alkylating agent KW - melflufen KW - MM KW - multiple myeloma KW - Phase III study KW - relapsed refractory multiple myeloma KW - RRMM UR - https://www.futuremedicine.com/doi/10.2217/fon-2020-0024?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed N2 - Melflufen is a novel peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells. It has emerged as a potential new multiple myeloma treatment, particularly for late-stage forms of the disease. Here we describe the rationale and design of OCEAN (NCT03151811), a randomized, head-to-head, superiority, open-label, global, Phase III study evaluating the efficacy and safety of melflufen + dexamethasone versus pomalidomide + dexamethasone. Eligible patients with relapsed refractory multiple myeloma have received 2-4 previous treatments and are refractory to both lenalidomide and their last treatment. Patients are excluded if they have previously received pomalidomide. The primary endpoint is progression-free survival, and key secondary endpoints include overall response rate, duration of response and overall survival. ER -
SCHJESVOLD, F., P. ROBAK, Luděk POUR, J. ASCHAN a P. SONNEVELD. OCEAN: a randomized Phase III study of melflufen plus dexamethasone to treat relapsed refractory multiple myeloma. \textit{Future Oncology}. London: Future Medicine Ltd., 2020, roč.~16, č.~11, s.~631-641. ISSN~1479-6694. Dostupné z: https://dx.doi.org/10.2217/fon-2020-0024.
|